ATE310749T1 - Monoklonaler antikörper gegen fibroblasten- wachstumsfaktor-8 - Google Patents

Monoklonaler antikörper gegen fibroblasten- wachstumsfaktor-8

Info

Publication number
ATE310749T1
ATE310749T1 AT97105601T AT97105601T ATE310749T1 AT E310749 T1 ATE310749 T1 AT E310749T1 AT 97105601 T AT97105601 T AT 97105601T AT 97105601 T AT97105601 T AT 97105601T AT E310749 T1 ATE310749 T1 AT E310749T1
Authority
AT
Austria
Prior art keywords
monoclonal antibody
growth factor
antibody against
fgf
fibroblasts growth
Prior art date
Application number
AT97105601T
Other languages
English (en)
Inventor
Nobuo Hanai
Motoo Yamasaki
Akiko Furuya
Akira Tanaka
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of ATE310749T1 publication Critical patent/ATE310749T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
    • C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
    • C23C14/00—Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material
    • C23C14/22—Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the process of coating
    • C23C14/24—Vacuum evaporation
    • C23C14/28—Vacuum evaporation by wave energy or particle radiation
    • C23C14/30—Vacuum evaporation by wave energy or particle radiation by electron bombardment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
    • C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
    • C23C26/00—Coating not provided for in groups C23C2/00 - C23C24/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Metallurgy (AREA)
  • Mechanical Engineering (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
AT97105601T 1996-04-03 1997-04-03 Monoklonaler antikörper gegen fibroblasten- wachstumsfaktor-8 ATE310749T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP08175496A JP3708210B2 (ja) 1996-04-03 1996-04-03 抗線維芽細胞増殖因子−８モノクローナル抗体

Publications (1)

Publication Number Publication Date
ATE310749T1 true ATE310749T1 (de) 2005-12-15

Family

ID=13755237

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97105601T ATE310749T1 (de) 1996-04-03 1997-04-03 Monoklonaler antikörper gegen fibroblasten- wachstumsfaktor-8

Country Status (6)

Country Link
US (3) US5952472A (de)
EP (1) EP0799835B1 (de)
JP (1) JP3708210B2 (de)
AT (1) ATE310749T1 (de)
DE (1) DE69734690T2 (de)
ES (1) ES2252764T3 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241568B2 (en) 1996-04-03 2007-07-10 Kyowa Hakko Kogyo Co., Ltd. Anti-fibroblast growth factor-8 monoclonal antibody
US7626192B2 (en) 1997-05-27 2009-12-01 State of Oregon Acting by the Through the State Board of Higher Education on Behalf of the University of Oregon Scaffold-organized clusters and electronic devices made using such clusters
WO2000006603A1 (fr) * 1998-07-31 2000-02-10 Asahi Kasei Kogyo Kabushiki Kaisha Anticorps pour la detection de micro-organismes
AU2001249459A1 (en) * 2000-03-24 2001-10-08 The State Of Oregon, Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Scaffold-organized clusters and electronic devices made using such clusters
CA2451854A1 (en) * 2001-06-28 2003-01-09 Kyowa Hakko Kogyo Co., Ltd. Humanized antibody against fibroblast growth factor-8 and antibody fragment thereof
KR100942402B1 (ko) 2001-12-28 2010-02-17 교와 핫꼬 기린 가부시키가이샤 관절염 치료약
KR100493460B1 (ko) * 2002-08-29 2005-06-07 재단법인서울대학교산학협력재단 암 세포에서 발현되는 ｆｇｆｒ2 이성체

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09503751A (ja) * 1993-08-02 1997-04-15 プリズム ファーマシュティカルズ，インコーポレイティド 細胞毒性抱合体の単一起源性製剤

Also Published As

Publication number Publication date
JP3708210B2 (ja) 2005-10-19
EP0799835A2 (de) 1997-10-08
DE69734690D1 (de) 2005-12-29
DE69734690T2 (de) 2006-08-10
US6310184B1 (en) 2001-10-30
US20020099181A1 (en) 2002-07-25
EP0799835B1 (de) 2005-11-23
EP0799835A3 (de) 2001-07-25
ES2252764T3 (es) 2006-05-16
JPH09271391A (ja) 1997-10-21
US5952472A (en) 1999-09-14

Similar Documents

Publication Publication Date Title
CY1107778T1 (el) Ανθρωπινα cd45+ ή/και ινοβλαστης + μεσεγχυματικα βλαστικα κυτταρα
IL147017A0 (en) TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
DE69738045D1 (de) Verwendung von cetrorelix zur behandlung von benigne prostatahypertrophie und prostatakrebs
TR199701212T1 (xx) �drar� tutamama halinin tedavisi i�in alfa IL- agonistlerinin kullan�lmas�.
ATE324877T1 (de) Behandlung von metastatischer krankheit
DE60041333D1 (de) Hen prostatkrebs exprimiert wird, und deren verwendungen
ATE242238T1 (de) Chinolin- und chinazolin-verbindungen von therapeutischem nutzen, insbesondere zur behandlung von gutartiger prostatahyperplasie
EP2112167A3 (de) Humanisierte ANTI-ERBB2-Antikörper und Behandlung mit ANTI-ERBB2-Antikörpern
AU2738195A (en) Tumor diagnosis and prognosis
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
MY138883A (en) Use of asiatic acid for treatment of cencer
UA66793C2 (uk) Лептин як стримувач швидкого збільшення пухлини клітини
ATE310749T1 (de) Monoklonaler antikörper gegen fibroblasten- wachstumsfaktor-8
NZ334592A (en) Protein growth factor related to TNF-beta and coupled with a toxic moiety for use in treating prostate cancer
DE69720783D1 (de) Reaktive sauerstoffverbindungen enthaltende verbindungen zur induzierung von zelldifferentiation maligner zellen so wie leukämie
DE69329062T2 (de) Verwendung von inhibitoren der 3-hydroxy-3-methylglutaryl-coenzym a-reduktase als mittel zur krebstherapie
NO994750L (no) Anti-Fas-antistoffer
TR199903074T2 (xx) Kanser tedavisinde HMG CoA ve farnesil transfer �nleyicileri.
BR9808958A (pt) Formulações de óxidos de 1,2,4-benzotriazina
WO2002076394A3 (en) Enzyme-based anti-cancer compositions and methods
IL129922A0 (en) Tissue specific expression of retinoblastoma protein
ES8600518A1 (es) Metodo in vitro para detectar un estado maligno en un paciente humano.
CA95615S (en) Tanned hide
DK1054680T3 (da) Behandling af blærecancer med mycobacterium phlei cellevæg
MX9702664A (es) Tirosina cinasa receptora humana, her4 de la familia del receptor del factor del crecimiento epidermico.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties